Clinically, elevated circulating IL-8 tracks with inferior outcomes to PD-(L)1 blockade across malignancies, consistent with a neutrophil-dominated suppressive milieu that can supersede high tumor antigenicity (30, 31). Here, CXCL8 is linked to neoplasm.